Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06075602
Recruiting Observational

COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease

NCT06075602 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Luzerner Kantonsspital
Phase
Observational
Started
2021-11-01
Last updated
2024-10-29

Condition(s) studied

Coronary DiseaseCoronary Artery DiseaseCoronary RestenosisCoronary ArteriosclerosisCoronary Artery CalcificationStable Chronic AnginaAngina PectorisAngina, StableAngina, UnstableStent Thrombosis

Investigational drug(s) / intervention(s)

Impact of current PCI techniques/ devices in complex coronary artery lesions

Impact of current PCI techniques/ devices in complex coronary artery lesions: To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions

Study summary

The purpose of the COMPLEX Registry is to prospectively and retrospectively collect baseline, clinical and procedural data of patients who have undergone PCI or CABG for complex and/ or calcified chronic CAD, irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. The outcomes will be compared in different clinical subgroups (e.g. PCI vs. CABG). The impact of current PCI techniques/ devices, but also CABG strategies in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject \>18 years of age * Individuals presenting with chronic, complex and/or calcified CAD and requiring PCI or CABG * Complex coronary artery disease / lesions must include at least one of the following attributes: * Long and/ or heavily calcified coronary lesions * In-stent restenosis * Chronic total occlusions (CTO) * Left main lesions * Bifurcation lesions * Bypass graft lesions * Small vessel disease / coronary microvascular dysfunction (e.g. not amenable to PCI) * Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK). Exclusion Criteria: The presence of any one of the following exclusion criteria will lead to exclusion of the patient. * Patient is \<18 years of age * Patient unwilling or unable to provide informed consent * Patients with no complex and calcified CAD

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Lucerne Heart Centre Lucerne Canton of Lucerne Recruiting

More Luzerner Kantonsspital trials in Switzerland

New Interactive Sensor-home-based Hand Training to Improve Dexterity Recruiting
Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty Recruiting
The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial Recruiting
SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters Recruiting
Comparison of Blended Care Outpatient Neurorehabilitation With Traditional Outpatient Neurorehabilitation Enrolling by invitation

Other trials for the same condition

The SELUTION DeNovo Study Active, not recruiting
Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure Recruiting
First in Men Study: BIOMAG-I Active, not recruiting
PCI Registry Basel Recruiting
Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06075602 on ClinicalTrials.gov ↗ ← All trials in Switzerland